Vivek Jain Sells 12,000 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

ICU Medical Price Performance

ICUI traded up $0.32 on Friday, hitting $158.44. 314,167 shares of the company’s stock were exchanged, compared to its average volume of 285,157. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $159.50. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. The firm has a 50-day moving average price of $124.63 and a 200-day moving average price of $109.57. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -64.67 and a beta of 0.69.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 2.63% and a positive return on equity of 5.38%. The company had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter in the previous year, the company posted $1.58 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. As a group, equities analysts anticipate that ICU Medical, Inc. will post 3.5 earnings per share for the current year.

Wall Street Analyst Weigh In

ICUI has been the subject of several recent analyst reports. KeyCorp boosted their price target on shares of ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. Finally, Raymond James boosted their price target on shares of ICU Medical from $135.00 to $158.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Xponance Inc. boosted its position in shares of ICU Medical by 6.0% during the 2nd quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after acquiring an additional 112 shares during the last quarter. CWM LLC boosted its position in shares of ICU Medical by 18.5% during the 2nd quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock valued at $91,000 after acquiring an additional 120 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of ICU Medical by 75.1% during the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 133 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of ICU Medical by 7.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,576 shares of the medical instruments supplier’s stock valued at $257,000 after acquiring an additional 187 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.